

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	NUNC PRO TUNC ASSIGNMENT
EFFECTIVE DATE:	09/12/2006

CONVEYING PARTY DATA

Name	Execution Date
Wyeth LLC	05/11/2010

RECEIVING PARTY DATA

Name:	Janssen Alzheimer Immunotherapy
Street Address:	Little Island Industrial Estate
City:	Little Island, County Cork
State/Country:	IRELAND

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	11520438

CORRESPONDENCE DATA

Fax Number: (415)576-0300
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
 Phone: 650-326-2400
 Email: mrcatiis@townsend.com
 Correspondent Name: Rosemarie L. Celli
 Address Line 1: TOWNSEND and TOWNSEND and CREW LLP
 Address Line 2: Two Embarcadero Center, 8th Floor
 Address Line 4: San Francisco, CALIFORNIA 94111-3834

ATTORNEY DOCKET NUMBER:	15270C-006021US
NAME OF SUBMITTER:	Rosemarie L. Celli

Total Attachments: 6
 source=C-006021US - Nunc Pro Tunc Assignment#page1.tif
 source=C-006021US - Nunc Pro Tunc Assignment#page2.tif
 source=C-006021US - Nunc Pro Tunc Assignment#page3.tif

CH \$40.00 11520438

501185464

**PATENT
 REEL: 024432 FRAME: 0251**

source=C-006021US - Nunc Pro Tunc Assignment#page4.tif
source=C-006021US - Nunc Pro Tunc Assignment#page5.tif
source=C-006021US - Nunc Pro Tunc Assignment#page6.tif

ASSIGNMENT

THIS ASSIGNMENT, by WYETH LLC (formerly known as Wyeth), a limited liability company organized under the laws of Delaware and having its principal place of business at Five Giralda Farms, Madison, New Jersey 07940 (hereinafter referred to as "the Assignor"), witnesseth:

WHEREAS, the Assignor, pursuant to a Research, Development and Commercialization Agreement, dated March 17, 2000 (hereinafter referred to as "the Collaboration Agreement"), between American Home Products Corporation acting through American Home Products Corporation's Wyeth-Ayerst Division (now collectively known as Wyeth LLC) and Neuralab Limited, an assignment recorded in the United States Patent and Trademark Office on September 11, 2009 at reel 023218, frame 0839, and an assignment recorded in the United States Patent and Trademark Office on November 6, 2009 at reel 023484, frame 0836, has acquired an undivided right, title and interest in and to the below-identified United States patent application (hereinafter "the Application") and to any Letters Patent to issue therefrom in the United States of America;

Title of Invention: HUMANIZED ANTIBODIES THAT RECOGNIZE BETA
AMYLOID PEPTIDE

US Application No.: 11/520,438

Filing Date: September 12, 2006

WHEREAS, JANSSEN ALZHEIMER IMMUNOTHERAPY (formerly known as Juno Neurosciences), a private unlimited company incorporated under the laws of Ireland, and having its registered office at Little Island Industrial Estate, Little Island, County Cork, Republic of Ireland (hereinafter referred to as "the Assignee"), pursuant to an Asset Purchase Agreement dated as of July 2, 2009 among Crimagua Limited, the Assignee, Janssen Pharmaceutical, Elan Corporation, plc, Elan Pharmaceuticals, Inc. and Athena Neurosciences, Inc., an assignment recorded in the United States Patent and Trademark Office on October 16, 2009 at reel 023385, frame 0075, and an assignment recorded in the United States Patent and Trademark Office on November 6, 2009 at reel 023484, frame 0885, has acquired an undivided right, title, and interest in and to the Application and to any Letters Patent to issue therefrom in the United States of America;

WHEREAS, the Application discloses subject matter invented by Guriq Basi, Jose William Saldanha, and Dale B. Schenk;

WHEREAS, the inventive contribution of Guriq Basi and Jose William Saldanha to the subject matter disclosed in the Application was made pursuant to the Collaboration Agreement;

WHEREAS, the inventive contribution of Dale B. Schenk to the subject matter disclosed in the Application was made prior to the Collaboration Agreement;

WHEREAS, at the time of filing, the Application included claims directed only to subject matter invented by Dale B. Schenk;

WHEREAS, because the claimed subject matter is directed solely to the inventive contribution made by Dale B. Schenk, the Assignor is not entitled to an undivided interest in the Application pursuant to the terms of the Collaboration Agreement and desires to convey its interest to the Assignee;

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, the Assignor does hereby sell, assign, transfer, and set over unto the Assignee, and Assignee's successors, legal representatives, and assigns, all of the Assignor's right, title, and interest in and to the Application and to any Letters Patent that may issue therefrom in the United States of America, the same to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the term for which Letters Patent may be granted as fully and entirely as the same would have been held and enjoyed by the Assignor had its sale and assignment not been made;

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, their successors, legal representatives, and assigns, that the Assignor will, whenever counsel of the Assignee, or the counsel of their successors, legal representatives, and assigns, shall advise that any proceeding in connection with the Application or Letters Patent issuing therefrom in the United States of America, or any proceeding in connection with the Letters Patent, including interference proceedings, is lawful and desirable, or that any reissue, prolongation or extension of the Letters Patent to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of the Letters Patent, without charge to the Assignor, its successors, legal representatives, and assigns;

AND the Assignor hereby requests the Commissioner of Patents to issue any Letters Patent of the United States of America to the Assignee as the Assignee of the Letters Patent for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

To the extent allowed by law, this Assignment is effective *nunc pro tunc* from September 12, 2006.

IN TESTIMONY WHEREOF, duly authorized representatives of the Assignor and the Assignee have signed their names on the date(s) indicated.

WYETH LLC

Date: May 11, 2010

By: Bruce A. Pokras

Name: Bruce A. Pokras

Title: Attorney-in-Fact

JANSSEN ALZHEIMER IMMUNOTHERAPY

Date: _____

By: _____

Name: _____

Title: _____

ASSIGNMENT

THIS ASSIGNMENT, by WYETH LLC (formerly known as Wyeth), a limited liability company organized under the laws of Delaware and having its principal place of business at Five Giralda Farms, Madison, New Jersey 07940 (hereinafter referred to as "the Assignor"), witnesseth:

WHEREAS, the Assignor, pursuant to a Research, Development and Commercialization Agreement, dated March 17, 2000 (hereinafter referred to as "the Collaboration Agreement"), between American Home Products Corporation acting through American Home Products Corporation's Wyeth-Ayerst Division (now collectively known as Wyeth LLC) and Neuralab Limited, an assignment recorded in the United States Patent and Trademark Office on September 11, 2009 at reel 023218, frame 0839, and an assignment recorded in the United States Patent and Trademark Office on November 6, 2009 at reel 023484, frame 0836, has acquired an undivided right, title and interest in and to the below-identified United States patent application (hereinafter "the Application") and to any Letters Patent to issue therefrom in the United States of America;

Title of Invention: HUMANIZED ANTIBODIES THAT RECOGNIZE BETA
AMYLOID PEPTIDE

US Application No.: 11/520,438

Filing Date: September 12, 2006

WHEREAS, JANSSEN ALZHEIMER IMMUNOTHERAPY (formerly known as Juno Neurosciences), a private unlimited company incorporated under the laws of Ireland, and having its registered office at Little Island Industrial Estate, Little Island, County Cork, Republic of Ireland (hereinafter referred to as "the Assignee"), pursuant to an Asset Purchase Agreement dated as of July 2, 2009 among Crimagua Limited, the Assignee, Janssen Pharmaceutical, Elan Corporation, plc, Elan Pharmaceuticals, Inc. and Athena Neurosciences, Inc., an assignment recorded in the United States Patent and Trademark Office on October 16, 2009 at reel 023385, frame 0075, and an assignment recorded in the United States Patent and Trademark Office on November 6, 2009 at reel 023484, frame 0885, has acquired an undivided right, title, and interest in and to the Application and to any Letters Patent to issue therefrom in the United States of America;

WHEREAS, the Application discloses subject matter invented by Guriq Basi, Jose William Saldanha, and Dale B. Schenk;

WHEREAS, the inventive contribution of Guriq Basi and Jose William Saldanha to the subject matter disclosed in the Application was made pursuant to the Collaboration Agreement;

WHEREAS, the inventive contribution of Dale B. Schenk to the subject matter disclosed in the Application was made prior to the Collaboration Agreement;

WHEREAS, at the time of filing, the Application included claims directed only to subject matter invented by Dale B. Schenk;

WHEREAS, because the claimed subject matter is directed solely to the inventive contribution made by Dale B. Schenk, the Assignor is not entitled to an undivided interest in the Application pursuant to the terms of the Collaboration Agreement and desires to convey its interest to the Assignee;

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, the Assignor does hereby sell, assign, transfer, and set over unto the Assignee, and Assignee's successors, legal representatives, and assigns, all of the Assignor's right, title, and interest in and to the Application and to any Letters Patent that may issue therefrom in the United States of America, the same to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the term for which Letters Patent may be granted as fully and entirely as the same would have been held and enjoyed by the Assignor had its sale and assignment not been made;

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, their successors, legal representatives, and assigns, that the Assignor will, whenever counsel of the Assignee, or the counsel of their successors, legal representatives, and assigns, shall advise that any proceeding in connection with the Application or Letters Patent issuing therefrom in the United States of America, or any proceeding in connection with the Letters Patent, including interference proceedings, is lawful and desirable, or that any reissue, prolongation or extension of the Letters Patent to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of the Letters Patent, without charge to the Assignor, its successors, legal representatives, and assigns;

AND the Assignor hereby requests the Commissioner of Patents to issue any Letters Patent of the United States of America to the Assignee as the Assignee of the Letters Patent for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

To the extent allowed by law, this Assignment is effective *nunc pro tunc* from September 12, 2006.

IN TESTIMONY WHEREOF, duly authorized representatives of the Assignor and the Assignee have signed their names on the date(s) indicated.

WYETH LLC

Date: _____

By: _____

Name: _____

Title: _____

JANSSEN ALZHEIMER IMMUNOTHERAPY

Date: May 24, 2010

By: Peter Herridge

Name: Peter Herridge

Title: Senior Patent Attorney